Clin2
NCT07477808Possibly a fitNot yet recruiting

Appetite-boosting drug for advanced lung cancer

Non-small Cell Lung Cancer

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
116 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years of age or older.
  • You have been diagnosed with non-small cell lung cancer that is advanced (Stage IIIB/IIIC) or has spread (Stage IV) and cannot be removed with surgery.
  • You have not had chemotherapy for this advanced or metastatic lung cancer before (some earlier treatments are okay).
  • Your weight is in a lower range, with a body mass index (BMI) of 25 or less.
  • You are able to eat and swallow normally and do not need tube feeding or IV nutrition.
  • You have at least one measurable tumor that can be tracked on scans.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06828757Not yet recruiting· Phase 3
Megestrol for weight loss in lung cancer patients starting chemotherapy

This study tests a new form of megestrol, a medicine that helps stimulate appetite and promote weight gain, in people with advanced non-small cell lung cancer who are starting their first chemotherapy and are at risk of malnutrition. The goal is to see if it improves nutrition and overall well-being during treatment.

Changsha, Hunan
NCT07150663Recruiting· Phase 3
Megestrol acetate with chemoradiation for stage III lung cancer

This study tests whether a special form of megestrol acetate (a medicine used to help with weight and appetite) can improve outcomes when given alongside standard chemotherapy and radiation for people with stage III non-small cell lung cancer. It is for patients who are not overweight and who are not already using other appetite-boosting medications.

Wuhan, Hubei
NCT06961188Not yet recruiting· Phase 3
A medicine to improve appetite for advanced lung cancer

This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.

Wuhan, Hubei
NCT06961201Not yet recruiting· Phase 3
Appetite stimulant with standard care for extensive small cell lung cancer

This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.

Chengdu, Sichuan
NCT07356037Not yet recruiting· Phase 3
Appetite-stimulating medication for advanced liver cancer with weight loss

This study tests a new form of megestrol acetate (a medication that helps stimulate appetite and weight gain) for people with advanced liver cancer who are experiencing weight loss or loss of appetite. It is given alongside standard treatments for liver cancer, and the goal is to see if it can improve appetite and quality of life.

Chengdu, Sichuan
NCT07092137Not yet recruiting· Phase 2
Megestrol acetate for weight loss in advanced lung cancer

This trial tests a drug called megestrol acetate to help people with advanced lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and quality of life.

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.